Spectrum Pharmaceuticals ($SPPI) put on the best face possible on the news that its bladder cancer drug apaziquone failed two late stage studies.
After many criticisms of its plans, AMAG Pharmaceuticals ($AMAG) failed to get shareholder support today in their vote on the company's proposed buyout of Allos Therapeutics in a deal valued at
A few days ago AMAG Pharmaceuticals raised eyebrows with its proposed merger with Allos Therapeutics. The two companies didn't have much in common, aside from disappointing sales of two very
AMAG Pharmaceuticals ($AMAG) and Allos Therapeutics ($ALTH) struck a deal to merge in an all-stock transaction valued at $686 million. And the two developers have already identified $55 million to
After disappointing analysts with its sales numbers for Folotyn, Allos Therapeutics ($ALTH) turned around and announced an ex-North American licensing pact for the drug which will deliver $50 million
While sales reps have been the target of many rounds of layoffs recently, Allos Therapeutics has taken a different approach with its announced layoffs. The Westminster, CO-based biotech is laying off
Allos Therapeutics' shares were up 8 percent on the news that the FDA had approved Folotyn for use as a single agent for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). It's
Slightly more than one out of every four patients taking an experimental blood cancer drug--pralatrexate--developed by Allos Therapeutics experienced a complete or partial response in a pivotal Phase
ALSO NOTED: Allos gains orphan status for cancer therapy; NICE recommends against Velcade; and much more...
> Allos Therapeutics has gained orphan drug status for an experimental cancer therapy. Report > The U.K.'s drug watchdog, the National Institute for Health and Clinical Excellence, has